Advertisement

Neonatal Pulmonary Hemorrhage

  • Tonse N. K. Raju
Chapter

Keywords

Disseminate Intravascular Coagulation Pulmonary Hemorrhage Pulmonary Compliance Exogenous Surfactant VLBW Infant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. Alkharfy TM. High-frequency ventilation in the management of very-low-birth-weight infants with pulmonary hemorrhage. Am J Perinatol. 2004;1:19–26.Google Scholar
  2. Amizuka T, Shimizu H, Niida Y, Ogawa Y. Surfactant therapy in neonates with respiratory failure due to hemorrhagic pulmonary oedema. Eur J Pediatr. 2003;162:69.CrossRefGoogle Scholar
  3. Baroutis G, Kaleyias J, Liarou T, et al. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr. 2003;62:476–80.CrossRefGoogle Scholar
  4. Centers for Disease Control and Prevention: Investigation of acute idiopathic pulmonary hemorrhage among infants—Massachusetts, December 2002-June 2003. MMRW Morb Mortl Wkly Rep. 2004;3:817.Google Scholar
  5. Courtney SE, Durand DJ, Asselin M, et al. High-frequency oscillatory ventilation versus conventional ventilation for very-low-birth-weight infants. N Engl J Med. 2002;347:643–52.PubMedCrossRefGoogle Scholar
  6. Dufourq N, Thomson M, Adhikari M, Moodley J. Massive pulmonary hemorrhage as a cause of death in the neonate—a retrospective review. S Afr Med J. 2004;94:299–302.PubMedGoogle Scholar
  7. Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121:419–32.PubMedCrossRefGoogle Scholar
  8. Findlay RD, Taeusch HW, David WR, Walther FJ. Lysis of blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatr Res. 1995;37:26–30.PubMedCrossRefGoogle Scholar
  9. Fuji AM, Carillo M. Animal-derived surfactant treatment of respiratory distress syndrome in premature neonates: a review. Drugs Today. 2009;45:697–709.CrossRefGoogle Scholar
  10. Gharehbaghi MM, Sakha SH, Ghojazadeh M, Firoozi F. Complications among premature neonates treated with Beractant and Poractant Alfa. Indian J Pediatr. 2010;77:751–4.PubMedCrossRefGoogle Scholar
  11. Goretksy MJ, Martinasek D, Warner BW. Pulmonary hemorrhage: a novel complication after extracorporeal life support. J Pediatr Surg. 1996;1:1276–81.Google Scholar
  12. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinol. 2003;14:117–20.CrossRefGoogle Scholar
  13. Kluckow M, Evans N. Ductal shunting, high pulmonary flow, and pulmonary hemorrhage. J Pediatr. 2000;137:68–72.PubMedCrossRefGoogle Scholar
  14. Lamboley-Gilmer G, Lacaze-Masmonteil T, Neonatologists of the Curosurf® Study Group. The short-term outcome of a large cohort of very preterm infants treated with Poractant Alfa (Curosurf   ®) for respiratory distress syndrome. A postmaketing phase IV study. Pediatr Drugs. 2003;5:639.CrossRefGoogle Scholar
  15. Leibovitch L, Kenet G, Mazor K. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med. 2003;4:444–6.PubMedCrossRefGoogle Scholar
  16. Lin TW, Su BH, Lin HC, et al. Risk factors of pulmonary hemorrhage in very-low-birthweight infants: a two-year retrospective study. Acta Pediatr Taiwan. 2004;45:255–8.Google Scholar
  17. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol. 2002;22:672–4.PubMedCrossRefGoogle Scholar
  18. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics. 1995;95:32–6.PubMedGoogle Scholar
  19. Pappin A, Shenker N, Jack M, Redline RW. Extensive intraalveolar pulmonary hemorrhage in infants dying after surfactant therapy. J Pediatr. 1994;124:621–6.PubMedCrossRefGoogle Scholar
  20. Poralla C, Hertfelder H-J, Oldenburg J, Müller A, Bartmann P, Heep A. Treatment of acute pulmonary haemorrhage in extremely preterm infants with recombinant activated factor VII. Acta Paediatr. 2010;99:298–300.PubMedGoogle Scholar
  21. Raju TNK, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr. 1993;123:603–10.PubMedCrossRefGoogle Scholar
  22. Rao KVS, Michalski L. Intrauterine pulmonary hemorrhage secondary to antenatal Coxsackie B-2 infection. Pediatr Res. 1997;1:265A.CrossRefGoogle Scholar
  23. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009, Issue 2.Google Scholar
  24. Soll R, Özek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2010, Issue 1.Google Scholar
  25. St. John EB, Carlo WA. Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD neonatal research network. Semin Perinatol. 2003;27:288–92.PubMedCrossRefGoogle Scholar
  26. Suresh GK, Soll RF. Exogenous surfactant therapy in newborn infants. Ann Acad Med Singapore. 2003;32:335–45.PubMedGoogle Scholar
  27. Tobias J, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;41:49–51.CrossRefGoogle Scholar
  28. van Houten J, Long W, Mullett M, et al. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation. J Pediatr. 1992;120:540–4.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentBethesdaUSA

Personalised recommendations